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IntroduCtIon
Despite the availability of effective drug therapies reducing LDL-cholesterol (LDL-C), cardiovascular disease (CVD) remains a significant source of mortality and morbidity. Additional LDL-C reduction may be warranted, especially in patients that are unresponsive to or unable to take existing LDL-C reducing therapies. 1 Monoclonal antibodies against PCSK9 (PCSK9 inhibitors) may provide such additional LDL-C reduction. In this synopsis, we summarise findings from a recent Cochrane systematic review 2 on the safety and effectiveness of PCSK9 inhibitors. Here we particularly focus on the relative effectiveness of PCSK9 inhibitors compared to existing treatments such as statins and/or ezetimibe and report on the (perceived) quality of the evidence.
MethodS
The following databases were systematically searched for eligible randomised controlled trials (RCTs): Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Web of Science, Clinicaltrials. gov and the International Clinical Trials Registry Platform. Parallel-group and factorial RCTs with at least 24 weeks of follow-up were included.
SuMMary of fIndIngS
The 20 identified randomised trials (68 341 participants) predominantly selected high-risk patients (box 1): 7% having familial hypercholesterolaemia, 89% a history of CVD and 39% a type 2 diabetes mellitus (T2DM) diagnosis. The PCSK9 inhibitor alirocumab was evaluated in 13 trials, evolocumab in 3 trials, bococizumab (discontinued agent) in 3 trials and RG7652 by a single trial. Comparisons were made against placebo in 13 trials, ezetimibe and statins in 5 trials and ezetimibe only in 2 trials. When not used as a randomised comparison treatment, statins or ezetimibe were often prescribed (ie, not randomly allocated) as background medication.
PCSK9 inhibitors showed beneficial effects in reducing proatherogenic lipid particles (figure 1). Compared against placebo PCSK9 inhibitor effects on clinical endpoints were: OR of 0.86 (95% CI 0.80 to 0.92) with CVD events, 0.77 (95% CI 0.69 to 0.85) for myocardial infarction (MI), 0.76 (95% CI 0.65 to 0.90) for any stroke and 1.02 (95% CI 0.91 to 1.15) for all-cause mortality. The OR with any adverse events was 1.08 (95% CI 1.04 to 1.12), selected individual adverse events included a protective association with elevated creatinine 0.85 (95% CI 0.73 to 1.00) and potentially harmful signals on influenza and myalgia: 1.19 (95% CI 0.91 to 1.55) and 1.11 (95% CI 0.98 to 1.26), respectively. After excluding results from the SPIRE trials (using the terminated bococizumab), the associations with any adverse events and myalgia were: 1.01 (95% CI 0.96 to 1.06) and 1.17 (95% CI 0.87 to 1.56), respectively. PCSK9 inhibitors did not seem to affect the incidence of T2DM, cancers or neurocognitive events, although precision, number of events and follow-up time were limited for these endpoints.
Trials comparing PCSK9 inhibitors to ezetimibe and statins showed a protective effect on CVD 0.45 (95% CI 0.27 to 0.75) and a risk increasing effect of 1.18 (95% CI 1.05 to 1.34) on any adverse event. Data on all-cause mortality and separate CVD elements were unavailable for the ezetimibe and statin comparator trials. Clinical endpoint data were absent for the trials comparing PCKS9 inhibitors to ezetimibe, and no trial were found comparing PCSK9 inhibitors against statins only.
LIMItatIonS
Based on the GRADE profiler (GRADEpro) methodology, the quality of the evidence for efficacy endpoints was judged as moderate for the placebo comparisons because of the limited follow-up (median follow-up FOURIER, 26 months; SPIRE-1, 7 months; SPIRE-2, 12 months). In ezetimibe and statin comparison, the quality of the evidence was graded as very low due to the lack of blinding, small number of events per study and short follow-up. These issues may also explain the larger effect of PCSK9 inhibitors on CVD when compared against ezetimibe and statins versus the smaller effect observed in the placebo comparison. Published data from trials conducted to date show an adequate safety profile with no increases in the risk of major adverse events such as cancers, T2DM or neurocognitive events. However, the number of neurological events as well as the duration of follow-up was limited (less than 3 years).
areaS In need of future Study
Besides exploring the long-term safety of PCSK9 inhibitors (eg, cancer, T2DM, cognition) attention should be given to its effects on CVD endpoints other than CHD and stroke (eg, heart failure, atrial fibrillation) which represents a considerable proportion of first-time presentations for cardiovascular disorders. 3 High-quality evidence is limited for PCSK9 inhibitor compared with active treatments (statins and ezetimibe). Finally, little is known on the PCSK9 inhibitor effectiveness and safety in primary prevention settings.
ConCLuSIon
PCSK9 inhibitors showed a substantial reduction in atherogenic lipid particles (LDL-C, Apo-B and Lp(a)) and protective effects on: any CVD, MI (placebo figure 1 Summary of findings. Nb. associations in the forest plots are given as odds ratio (OR) with 95% confidence interval (CI). The bottom bar plots provide the mean difference estimates as mean percentage change from baseline at 6 months of follow-up, with the error bars indicating the 95% CI. Results without data were left empty. LDL-C, LDL-cholesterol; Apo-B, apolipoprotein B; TC, total cholesterol; LP[a], lipoprotein(a); TG, triglycerides; HDL-C, HDL-cholesterol; nHDL-C, non-HDL-cholesterol; ApoA1, apolipoprotein A1. editorial comparison only), stroke (placebo comparison only) and elevated creatinine. PCSK9 inhibitors were associated with an increased risk of any adverse events, which reduced to a neutral effect in the placebo comparison after excluding data from the discontinued SPIRE trial.
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